AP
ACAD icon

AHL Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

AHL Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$267K Buy
8,882
+3,094
+53% +$98.9K ﹤0.01% 1185
2017
Q3 		$218K Buy
+5,788
New +$188K ﹤0.01% 1195
2016
Q4 		– Sell
-9,772
Closed -$311K – 1031
2016
Q3 		$311K Buy
+9,772
New +$331K 0.01% 975

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

AHL Partners's ACAD Position: Q4 2017 in Review

AHL Partners increased its Acadia Pharmaceuticals (ACAD) stake by 53% in Q4 2017, buying an estimated $98.9K and bringing the position to 8,882 shares worth $267K. The position accounts for ﹤0.01% of the portfolio, ranked #1185.

AHL Partners first reported a position in ACAD in Q3 2016 and has held it in 3 quarters since. The position peaked at $311K in Q3 2016. 210 funds tracked by Wall St. Rank hold ACAD as of Q4 2017.

  • AHL Partners held 8,882 shares of Acadia Pharmaceuticals worth $267K as of Q4 2017.
  • AHL Partners bought 3,094 Acadia Pharmaceuticals shares in Q4 2017, an estimated $98.9K.
  • Acadia Pharmaceuticals made up ﹤0.01% of AHL Partners's portfolio in Q4 2017, its #1185 holding.
  • AHL Partners first reported a position in Acadia Pharmaceuticals in Q3 2016 and has held it in 3 quarters since.
  • AHL Partners's Acadia Pharmaceuticals position peaked at $311K in Q3 2016.
  • 210 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.